Literature DB >> 30912672

High Mobility Group Box 1 Protein in Osteoarthritic Knee Tissue and Chondrogenic Progenitor Cells: An Ex Vivo and In Vitro Study.

Gunar Wagner1, Christoph Lehmann1, Christa Bode1, Nicolai Miosge1, Andrea Schubert1.   

Abstract

OBJECTIVE: In osteoarthritis (OA), a loss of healthy cartilage extracellular matrix (ECM) results in cartilage degeneration. Attracting chondrogenic progenitor cells (CPCs) to injury sites and stimulating them toward chondrogenic expression profiles is a regenerative approach in OA therapy. High mobility group box 1 protein (HMGB1) is associated with chemoattractant and proinflammatory effects in various pathological processes. Here, we investigate the migratory effects of HMGB1 in knee OA and CPCs for the first time.
DESIGN: Immunohistochemistry, immunoblotting, and immunocytochemistry were performed to identify HMGB1 and its receptors, receptor for advanced glycation end products (RAGE) and toll-like receptor 4 (TLR4) in OA knee tissue, chondrocytes, and CPCs. In situ hybridization for HMGB1 mRNA was performed in CPCs ex vivo. The chemoattractant effects of HMGB1 on CPCs were analyzed in cell migration assays.
RESULTS: HMGB1 expression in OA tissue and OA chondrocytes was higher than in healthy specimens and cells. HMGB1, RAGE, and TLR4 were expressed in CPCs and chondrocytes. In situ hybridization revealed HMGB1 mRNA in CPCs after migration into OA knee tissue, and immunohistochemistry confirmed HMGB1 expression at the protein level. Stimulation via HMGB1 significantly increased the migration of CPCs.
CONCLUSIONS: Our results show the chemoattractant role of HMGB1 in knee OA. HMGB1 is released by chondrocytes and has migratory effects on CPCs. These effects might be mediated via RAGE and TLR4. The in vitro and ex vivo results of this study need to be confirmed in vivo.

Entities:  

Keywords:  HMGB1; RAGE; TLR4; cell migration; chondrogenic progenitor cells; osteoarthritis

Mesh:

Substances:

Year:  2019        PMID: 30912672      PMCID: PMC8461157          DOI: 10.1177/1947603519835897

Source DB:  PubMed          Journal:  Cartilage        ISSN: 1947-6035            Impact factor:   4.634


  75 in total

Review 1.  Clinical practice. Osteoarthritis of the knee.

Authors:  David T Felson
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

2.  Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies.

Authors:  R Holmdahl; K Rubin; L Klareskog; E Larsson; H Wigzell
Journal:  Arthritis Rheum       Date:  1986-03

3.  High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine.

Authors:  Noboru Taniguchi; Ko-ichi Kawahara; Kazunori Yone; Teruto Hashiguchi; Munekazu Yamakuchi; Masamichi Goto; Keiichi Inoue; Shingo Yamada; Kosei Ijiri; Shunji Matsunaga; Toshihiro Nakajima; Setsuro Komiya; Ikuro Maruyama
Journal:  Arthritis Rheum       Date:  2003-04

4.  Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock.

Authors:  M Ombrellino; H Wang; M S Ajemian; A Talhouk; L A Scher; S G Friedman; K J Tracey
Journal:  Lancet       Date:  1999-10-23       Impact factor: 79.321

5.  High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis.

Authors:  R Kokkola; E Sundberg; A-K Ulfgren; K Palmblad; J Li; H Wang; L Ulloa; H Yang; X-J Yan; R Furie; N Chiorazzi; K J Tracey; U Andersson; H Erlandsson Harris
Journal:  Arthritis Rheum       Date:  2002-10

6.  Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products.

Authors:  Ingrid E Dumitriu; Paramita Baruah; Barbara Valentinis; Reinhard E Voll; Martin Herrmann; Peter P Nawroth; Bernd Arnold; Marco E Bianchi; Angelo A Manfredi; Patrizia Rovere-Querini
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

Review 7.  Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.

Authors:  Feng Xie; Bruno Kovic; Xuejing Jin; Xiaoning He; Mengxiao Wang; Camila Silvestre
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

8.  Systemic inflammation and remote organ injury following trauma require HMGB1.

Authors:  Ryan M Levy; Kevin P Mollen; Jose M Prince; David J Kaczorowski; Raghuveer Vallabhaneni; Shiguang Liu; Kevin J Tracey; Michael T Lotze; David J Hackam; Mitchell P Fink; Yoram Vodovotz; Timothy R Billiar
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-07-25       Impact factor: 3.619

Review 9.  HMGB1 in cancer: good, bad, or both?

Authors:  Rui Kang; Qiuhong Zhang; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Clin Cancer Res       Date:  2013-05-30       Impact factor: 12.531

10.  High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells.

Authors:  V Boonyaratanakornkit; V Melvin; P Prendergast; M Altmann; L Ronfani; M E Bianchi; L Taraseviciene; S K Nordeen; E A Allegretto; D P Edwards
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

View more
  3 in total

1.  Pondering the Potential of Hyaline Cartilage-Derived Chondroprogenitors for Tissue Regeneration: A Systematic Review.

Authors:  Elizabeth Vinod; Roshni Parameswaran; Boopalan Ramasamy; Upasana Kachroo
Journal:  Cartilage       Date:  2020-08-25       Impact factor: 3.117

2.  Relationship between the pyroptosis of fibroblast‑like synoviocytes and HMGB1 secretion in knee osteoarthritis.

Authors:  Yancheng Xiao; Liang Ding; Songjiang Yin; Zhengquan Huang; Li Zhang; Wei Mei; Peng Wu; Peimin Wang; Ke Pan
Journal:  Mol Med Rep       Date:  2020-12-10       Impact factor: 2.952

Review 3.  The Involvement of Neutrophils in the Pathophysiology and Treatment of Osteoarthritis.

Authors:  Shelby Chaney; Rosemary Vergara; Zeena Qiryaqoz; Kelsey Suggs; Adil Akkouch
Journal:  Biomedicines       Date:  2022-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.